These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11410276)

  • 21. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin).
    Holmes WE; Nelles L; Lijnen HR; Collen D
    J Biol Chem; 1987 Feb; 262(4):1659-64. PubMed ID: 2433286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why alpha-antiplasmin must be converted to a derivative form for optimal function.
    Lee KN; Jackson KW; Christiansen VJ; Lee CS; Chun JG; McKee PA
    J Thromb Haemost; 2007 Oct; 5(10):2095-104. PubMed ID: 17883704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An examination of the inhibitory mechanism of serpins by analysing the interaction of trypsin and chymotrypsin with alpha 2-antiplasmin.
    Enghild JJ; Valnickova Z; Thøgersen IB; Pizzo SV; Salvesen G
    Biochem J; 1993 May; 291 ( Pt 3)(Pt 3):933-8. PubMed ID: 7683878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of alpha 2-antiplasmin by limited reaction with cis-dichlorodiammineplatinum (II).
    Geary WA; Gonias SL
    Biochim Biophys Acta; 1989 Jan; 994(1):1-6. PubMed ID: 2521201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences.
    Abdul S; Leebeek FW; Rijken DC; Uitte de Willige S
    Blood; 2016 Feb; 127(5):538-45. PubMed ID: 26626994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond.
    Bini A; Itoh Y; Kudryk BJ; Nagase H
    Biochemistry; 1996 Oct; 35(40):13056-63. PubMed ID: 8855941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. X-ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin.
    Law RH; Sofian T; Kan WT; Horvath AJ; Hitchen CR; Langendorf CG; Buckle AM; Whisstock JC; Coughlin PB
    Blood; 2008 Feb; 111(4):2049-52. PubMed ID: 18063751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.
    Lee KN; Jackson KW; Christiansen VJ; Dolence EK; McKee PA
    J Thromb Haemost; 2011 May; 9(5):987-96. PubMed ID: 21251197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.
    Edelberg JM; Pizzo SV
    Biochem J; 1992 Aug; 286 ( Pt 1)(Pt 1):79-84. PubMed ID: 1381585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the localization of the cleavage site in human alpha-2-antiplasmin, involved in the generation of the non-plasminogen binding form.
    Abdul S; Dekkers DHW; Ariëns RAS; Leebeek FWG; Rijken DC; Uitte de Willige S
    J Thromb Haemost; 2020 May; 18(5):1162-1170. PubMed ID: 32034861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of fibrin and alpha2-antiplasmin on plasminogen activation by staphylokinase.
    Okada K; Ueshima S; Takaishi T; Yuasa H; Fukao H; Matsuo O
    Am J Hematol; 1996 Nov; 53(3):151-7. PubMed ID: 8895684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the antiplasmin activity of human thrombospondin-1 in solution.
    Anonick PK; Yoo JK; Webb DJ; Gonias SL
    Biochem J; 1993 Feb; 289 ( Pt 3)(Pt 3):903-9. PubMed ID: 7679575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Features of the interaction between alpha2-antiplasmin and plasminogen/plasmin].
    Hrynenko TV; Iusova OI; Zadorozhna MB; Makohonenko IeM
    Ukr Biokhim Zh (1999); 2002; 74(6):83-90. PubMed ID: 12924019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies against plasminogen and alpha-2-antiplasmin: binding to native and modified antigens.
    Hattey E; Wojta J; Binder BR
    Thromb Res; 1987 Mar; 45(5):485-95. PubMed ID: 2438800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-2-antiplasmin: a serpin with two separate but overlapping reactive sites.
    Potempa J; Shieh BH; Travis J
    Science; 1988 Aug; 241(4866):699-700. PubMed ID: 2456616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of the plasminogen-binding site of human alpha 2-plasmin inhibitor.
    Sasaki T; Morita T; Iwanaga S
    J Biochem; 1986 Jun; 99(6):1699-705. PubMed ID: 3745142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot.
    Takada A; Ito T; Takada Y
    Thromb Haemost; 1980 Feb; 43(1):20-3. PubMed ID: 6447383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha 2-antiplasmin's carboxy-terminal lysine residue is a major site of interaction with plasmin.
    Hortin GL; Gibson BL; Fok KF
    Biochem Biophys Res Commun; 1988 Sep; 155(2):591-6. PubMed ID: 2458720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purification of human alpha 2-antiplasmin with chicken IgY specific to its carboxy-terminal peptide.
    Lee SC; Lee KN; Schwartzott DG; Jackson KW; Tae WC; McKee PA
    Prep Biochem Biotechnol; 1997 Nov; 27(4):227-37. PubMed ID: 9413556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.